

# Publications

Zhou Z<sup>\*</sup>, Kleis L<sup>\*</sup>, Depetris-Chauvin A<sup>\*</sup>, Jaskulski S, Damerell V, Michels KB, Gigic B, Nöthlings U<sup>#</sup>, Panagiotou G<sup>#</sup> (2024) Beneficial microbiome and diet interplay in early-onset colorectal cancer. *EMBO Mol Med* 17(1), 9-30.

Marfil-Sanchez A<sup>\*</sup>, Seelbinder B<sup>\*</sup>, Ni Y, Varga J, Berta J, Hollosi V, Dome B, Megyesfalvi Z, Dulka E, Galffy G, Weiss GJ, Panagiotou G<sup>#</sup>, Zoltan Lohinai Z<sup>#</sup> (2021) Gut microbiome functionality might be associated with exercise tolerance and recurrence of resected early-stage lung cancer patients. *PLOS One* 16(11), e0259898.

Gill H, Yim R, Pang HH, Lee P, Chan TSY, Hwang YY, Leung GMK, Ip HW, Leung RYY, Yip SF, Kho B, Lee HKK, Mak V, Chan CC, Lau JSM, Lau CK, Lin SY, Wong RSM, Li W, Ma ESK, Li J, Panagiotou G, Sim JPY, Lie AKW, Kwong YL (2020) Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation. *Cancer Med* 9(10), 3371-3382.

Heshiki Y, Vazquez-Uribe R, Li J, Ni Y, Quainoo S, Imamovic L, Li J, Sørensen M, Chow BKC, Weiss GJ, Xu A, Sommer MOA, Panagiotou G (2020) Predictable modulation of cancer treatment outcomes by the gut microbiota. *Microbiome* 8(1), 28.

\*equal contribution #corresponding author